Gilead Sciences Chairman & CEO Daniel O'Day Executes $5.33M Rule 10b5-1 Stock Sale

Executive Summary

On November 2, 2026, Gilead Sciences, Inc. ($GILD) Chairman & Chief Executive Officer Daniel Patrick O'Day filed a Form 4 detailing option exercises and common stock sales executed across October 30 and November 2, 2026. The dispositions totaled 30,881 shares of Common Stock for gross proceeds of approximately $5.33 million, executed pursuant to a pre-arranged Rule 10b5-1 trading plan.

Transaction Breakdown

1. Option Exercise (October 30, 2026):

   • Exercised 15,881 non-qualified stock options at an exercise price of $72.34 per share, resulting in an acquisition of 15,881 common shares.

2. Open Market Sales:

   • October 30, 2026: Sold 15,881 shares at a weighted-average price of $175.25 ($2,783,075.37).
   • November 2, 2026: Sold an aggregate of 15,000 shares across five tranches ranging between $167.40 and $171.06 per share, generating $2,546,102.27.
   • Total Sold: 30,881 shares at a volume-weighted average price of approximately $172.57 per share.

Ownership Post-Transaction

Following the transactions, Daniel O'Day retains direct ownership of 551,683 shares of Gilead Sciences Common Stock, along with 240,739 remaining derivative stock options expiring on March 10, 2030.

Market & Governance Context

• Trading Significance: Rated Low.
• Rule 10b5-1 Plan: The filing confirms the transactions were carried out under a pre-scheduled trading plan adopted on February 25, 2026. Because the sales are programmatic and partially paired with an option exercise, they reflect routine executive compensation diversification rather than an ad-hoc sentiment shift.